Circulating Tumor Cells and Serological Cell Death Biomarkers Hold Promise for Early Detection and Prognosis of Small Cell Lung Cancer

Strategic Insights -

Researchers at the University of Manchester in the United Kingdom have made significant findings in the early detection and prognosis of small cell lung cancer (SCLC) by analyzing circulating tumor cells (CTCs) and serological cell death biomarkers. The study, published in the American Journal of Pathology, evaluated the expression and clinical significance of CTCs and serological cell death biomarkers in 88 patients with SCLC. The results show that CTCs were detected in 86% of patients, and CD56 was detectable in CTCs, confirming their neoplastic origin.

Key Takeaways:

  • The study evaluated the expression and clinical significance of CTCs and serological cell death biomarkers in 88 patients with small cell lung cancer (SCLC).
  • CTCs were detected in 86% of patients, and CD56 was detectable in CTCs, confirming their neoplastic origin.
  • M30 levels correlated with the percentage of apoptotic CTCs, and M30, M65, lactate dehydrogenase, and CTC number were prognostic for patient survival determined by univariate analysis.
  • Using multivariate analysis, both lactate dehydrogenase and M65 levels remained significant.
  • CTC number fell following chemotherapy, whereas levels of serological cell death biomarkers peaked at 48 hours and fell by day 22, mirroring the tumor response.
  • A 48-hour rise in nucleosomal DNA and M30 levels was associated with early response and severe toxicity, respectively.
  • The researchers concluded that their results provide a rationale to include the use of serological biomarkers and CTCs in early clinical trials of new agents for SCLC.

Statistics:

  • 88 patients with SCLC were evaluated in the study.
  • CTCs were detected in 86% of patients.
  • CD56 was detectable in CTCs, confirming their neoplastic origin.
  • M30 levels correlated with the percentage of apoptotic CTCs.
  • M30, M65, lactate dehydrogenase, and CTC number were prognostic for patient survival determined by univariate analysis.
  • Using multivariate analysis, both lactate dehydrogenase and M65 levels remained significant.

Sources:

  • (Am J Pathol 2009, 175:808-816, DOI: 10.2353/ajpath.2009.090078)
  • American Journal of Pathology
  • Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal of Pathology, 2009;175(2):808-816).